Zentalis Pharmaceuticals (ZNTL) Other Non-Current Liabilities (2019 - 2026)

Zentalis Pharmaceuticals has reported Other Non-Current Liabilities for 8 years, with the latest figure at $500000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 10.39% year-over-year to $500000.0; the trailing twelve-month figure through Mar 2026 stood at $500000.0 (down 10.39% YoY), and the FY2025 full-year result was $500000.0, down 41.11% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $500000.0, roughly flat from $500000.0 in the prior quarter.
• The five-year high for Other Non-Current Liabilities was $45.0 million in Q1 2022, with the low at $500000.0 in Q2 2023.
• Average Other Non-Current Liabilities over 5 years is $4.0 million, with a median of $996000.0 recorded in 2024.
• Year-over-year, Other Non-Current Liabilities jumped 10168.95% in 2022 and sank 96.02% in 2023.
• Tracing ZNTL's Other Non-Current Liabilities over 5 years: stood at $2.6 million in 2022, then plunged by 32.06% to $1.8 million in 2023, then sank by 52.3% to $849000.0 in 2024, then plunged by 41.11% to $500000.0 in 2025, then changed by 0.0% to $500000.0 in 2026.
• The last three Other Non-Current Liabilities figures came in at $500000.0 (Q1 2026), $500000.0 (Q4 2025), and $500000.0 (Q3 2025), per Business Quant data.

Peer Comparison